Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
 Annual Conference - EconoTimes)
CAMBRIDGE, Mass., April 06, 2016 -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a central organ for devastating rare diseases, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will deliver a presentation titled, “Developing an AAV Pipeline and Building a Successful Biotech,” during the BSGCT Annual Conference – AAV in 2016: Biology, vector design and implementation into human gene therapy. The conference will take place at the University College London Institute of Child Health on Friday, April 15, 2016. Dr. Jenkins’ presentation will begin at 1:45pm BST.
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency and GSDIa, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.
CONTACT: Jean Franchi Chief Financial Officer Dimension Therapeutics 617-714-0709 [email protected] Burns McClellan, on behalf of Dimension Therapeutics Media: Justin Jackson 212-213-0006, ext.327 [email protected]
